-
1.发明授权Use of IgG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and manifestations via the mucosal route 有权IgG1免疫球蛋白和/或CD32受体的配体用于通过粘膜途径治疗炎性疾病和表现公开(公告)号：US09187568B2
公开(公告)日：2015-11-17
申请号：US13319074
申请日：2010-05-07
CPC分类号： C07K16/4291 , A61K2039/505 , A61K2039/542 , A61K2039/545 , C07K2317/41 , C07K2317/76
摘要： The present invention concerns the use of immunoglobulins of IgG1 type, and more generally of ligands of the CD32 receptor, for the treatment of inflammatory diseases and manifestations, in particular of allergies and auto-immune diseases, more particularly the treatment of allergic asthma, the immunoglobulins and ligands being administered via mucosal route, in particular via sublingual route.
摘要翻译： 本发明涉及IgG1型免疫球蛋白和更通常的CD32受体的配体用于治疗炎性疾病和表现，特别是过敏和自身免疫性疾病，特别是过敏性哮喘的治疗的用途， 免疫球蛋白和配体通过粘膜途径施用，特别是通过舌下途径施用。
-
2.发明申请USE OF IGG1 IMMUNOGLOBULINS AND/OR LIGANDS OF THE CD32 RECEPTOR FOR TREATING INFLAMMATORY DISEASES AND MANIFESTATIONS VIA THE MUCOSAL ROUTE 有权使用IGG1免疫球蛋白和/或CD32受体的配体，用于治疗炎性疾病和通过胶原路线的排卵公开(公告)号：US20120171198A1
公开(公告)日：2012-07-05
申请号：US13319074
申请日：2010-05-07
IPC分类号： A61K39/395 , A61P11/06 , A61P37/00 , A61P29/00 , A61P37/08
CPC分类号： C07K16/4291 , A61K2039/505 , A61K2039/542 , A61K2039/545 , C07K2317/41 , C07K2317/76
摘要： The present invention concerns the use of immunoglobulins of IgG1 type, and more generally of ligands of the CD32 receptor, for the treatment of inflammatory diseases and manifestations, in particular of allergies and auto-immune diseases, more particularly the treatment of allergic asthma, the immunoglobulins and ligands being administered via mucosal route, in particular via sublingual route.
摘要翻译： 本发明涉及IgG1型免疫球蛋白和更通常的CD32受体的配体用于治疗炎性疾病和表现，特别是过敏和自身免疫性疾病，特别是过敏性哮喘的治疗的用途， 免疫球蛋白和配体通过粘膜途径施用，特别是通过舌下途径施用。
-
公开(公告)号：US08632993B2
公开(公告)日：2014-01-21
申请号：US13318213
申请日：2010-04-30
申请人： Philippe Moingeon , Thierry Batard , Emmanuel Nony
发明人： Philippe Moingeon , Thierry Batard , Emmanuel Nony
CPC分类号： G01N33/6848 , G01N2333/415
摘要： The present invention relates to the use of at least one peptide comprising or consisting of a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, for determining the presence of extracts from at least one grass species in a composition.
摘要翻译： 本发明涉及至少一种肽的用途，所述肽包含选自SEQ ID NO：1，SEQ ID NO：2，SEQ ID NO：3，SEQ ID NO：4和SEQ ID NO： 用于确定组合物中至少一种草种的提取物的存在的NO.5。
-
公开(公告)号：US20120171710A1
公开(公告)日：2012-07-05
申请号：US13318213
申请日：2010-04-30
申请人： Philippe Moingeon , Thierry Batard , Emmanuel Nony
发明人： Philippe Moingeon , Thierry Batard , Emmanuel Nony
IPC分类号： G01N27/62 , C07K14/415 , C07K7/06 , C07K7/08
CPC分类号： G01N33/6848 , G01N2333/415
摘要： The present invention relates to the use of at least one peptide comprising or consisting of a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, for determining the presence of extracts from at least one grass species in a composition.
摘要翻译： 本发明涉及至少一种肽的用途，所述肽包含选自SEQ ID NO：1，SEQ ID NO：2，SEQ ID NO：3，SEQ ID NO：4和SEQ ID NO： 用于确定组合物中至少一种草种的提取物的存在的NO.5。
-
公开(公告)号：US09795644B2
公开(公告)日：2017-10-24
申请号：US13376238
申请日：2010-06-07
摘要： The invention relates to grass pollen extracts containing reduced amount of flavonoid glycosides in order to minimize the risks of genotoxicity of the grass pollen extracts. The invention also relates to a method of preparing grass pollen extracts containing reduced amount of flavonoid glycosides by ultrafiltration. Flavonoid glycosides are naturally present in grass pollen extracts and they have been identified as being responsible for the formation of flavonoid aglycones, which are genotoxic in vitro, under the influence of enzymes contained in the grass pollen extracts.
-
6.发明申请REDUCTION OF IN VITRO GENOTOXICITY OF POLLEN EXTRACTS BY REMOVAL OF FLAVONOIDS 有权通过去除花生四烯酸可以减少花生提取物的生殖细胞毒性公开(公告)号：US20120148626A1
公开(公告)日：2012-06-14
申请号：US13376238
申请日：2010-06-07
IPC分类号： A61K39/36 , A61P37/02 , A61K36/899
摘要： The invention relates to grass pollen extracts containing reduced amount of flavonoid glycosides in order to minimize the risks of genotoxicity of the grass pollen extracts. The invention also relates to a method of preparing grass pollen extracts containing reduced amount of flavonoid glycosides by ultrafiltration. Flavonoid glycosides are naturally present in grass pollen extracts and they have been identified as being responsible for the formation of flavonoid aglycones, which are genotoxic in vitro, under the influence of enzymes contained in the grass pollen extracts.
摘要翻译： 本发明涉及含有减少量的黄酮苷的草花粉提取物，以使草花粉提取物的遗传毒性风险最小化。 本发明还涉及通过超滤制备含有减少量的类黄酮苷的草花粉提取物的方法。 黄酮苷是天然存在于草花粉提取物中，它们被鉴定为负责在花粉提取物中含有酶的影响下在体外基因毒性的类黄酮糖苷配基的形成。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.017 秒)
